More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$320099647
EPS
-0.71
P/E ratio
--
Price to sales
16377.14
Dividend yield
--
Beta
0.155213
Previous close
$1.61
Today's open
$1.63
Day's range
$1.58 - $1.67
52 week range
$1.58 - $6.44
show more
CEO
Jerome Durso
Employees
57
Headquarters
Morristown, NJ
Exchange
NASDAQ Global Market
Shares outstanding
194589451
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
ALT Q3 Earnings Miss, Stock Sinks on Higher Costs & Funding Concerns
Altimmune's Q3 loss is wider than estimates as rising R&D costs weigh on earnings, while pemvidutide advances across MASH, AUD and ALD programs.
Zacks Investment Research • Nov 13, 2026

What Altimmune (ALT) Said on Its Q3 Earnings Call
Altimmune NASDAQ: ALT is ramping up a late-stage trial of its experimental drug pemvidutide for a serious liver disease and preparing for a December meeting with the U.S. Food and Drug Administration on a potential phase III program in alcohol use disorder.
MarketBeat • Nov 12, 2026

Altimmune, Inc. (ALT) Q3 2026 Earnings Call Transcript
Altimmune, Inc. (ALT) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 12, 2026

Altimmune Announces Third Quarter 2026 Financial Results and Business Update
Global PERFORMA Phase 3 trial in MASH progressing as planned Positive RECLAIM Phase 2 data in AUD highlighted in a late-breaking oral presentation at AASLD The Liver Meeting® 2026 End-of-Phase 2 meeting with FDA for AUD program scheduled for December 2026 $480 million in cash, cash equivalents and investments as of September 30, 2026 Webcast to be held today at 8:30 a.m. ET MORRISTOWN, N.J.
GlobeNewsWire • Nov 12, 2026

Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology
Significant reductions across non-invasive measures of liver fat, inflammation and fibrosis observed at 48 weeks of pemvidutide treatment, with generally favorable tolerability profile
GlobeNewsWire • Nov 12, 2026

Altimmune: Still Too Late And Too Capital-Intensive
Altimmune remains a 'Sell' as pemvidutide lacks clear differentiation in the competitive MASH landscape and faces significant funding challenges. ALT's share count has doubled year-over-year, with further dilution likely despite a current $480M cash balance and a cash runway into 2029. PERFORMA Phase 3 MASH trial is underway, but pemvidutide's efficacy and market positioning are uncertain versus established drugs like REZDIFFRA and WEGOVY.
Seeking Alpha • Nov 12, 2026

Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder
Results from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD; generally favorable tolerability profile
GlobeNewsWire • Nov 9, 2026

Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
MORRISTOWN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist, in serious liver diseases, today announced that it will report its third quarter 2026 financial results on Thursday, November 12, 2026.
GlobeNewsWire • Nov 5, 2026

Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD)
GlobeNewsWire • Nov 5, 2026

Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this transition, John M. Gill, Mitchel Sayare, Ph.D.
GlobeNewsWire • Oct 27, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Altimmune Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.